Table 3.

Factors associated with survival outcomes in patients with FIGO stage III to IV disease

Characteristic		Progression-free survival						Overall survival
		Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
		HR	95% CI	p-value	aHR	95% CI	p-value	HR	95% CI	p-value	aHR	95% CI	p-value
Age (yr)
	< 55	1			1			1			1
	≥ 55	1.431	1.127-1.815	0.003	1.406	1.076-1.837	0.013	2.261	1.160-4.405	0.017	1.650	0.831-3.276	0.152
FIGO stage
	III	1			1			1			1
	V	1.476	1.148-1.897	0.002	1.184	0.872-1.607	0.279	1.894	0.979-3.665	0.058	1.294	0.625-2.681	0.487
Histology
	High-grade serous	1			1			1			1
	Non–high-grade serous	1.068	0.764-1.492	0.701	1.345	0.931-1.942	0.114	1.029	0.430-2.463	0.949	1.250	0.466-3.355	0.658
Initial serum CA-125 (IU/mL)
	< 900	1			1			1			1
	≥ 900	1.294	1.006-1.666	0.045	1.163	0.887-1.525	0.275	1.842	0.952-3.566	0.070	1.456	0.723-2.933	0.293
Primary treatment strategy
	PDS	1			1			1			1
	NAC	1.683	1.315-2.153	< 0.001	1.502	1.093-2.066	0.012	1.918	1.005-3.664	0.048	2.105	0.963-4.604	0.062
Residual tumor after PDS/IDS
	< 1 cm	1			1			1			1
	≥ 1 cm	1.435	1.010-2.038	0.044	1.596	1.078-2.364	0.020	2.438	1.210-4.913	0.013	2.769	1.258-6.095	0.011
BRCA mutational status
	Wild-type	1			1			1			1
	Mutation	0.828	0.642-1.068	0.147	0.722	0.546-0.956	0.023	0.986	0.512-1.899	0.967	1.066	0.547-2.078	0.851

FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; CA-125, cancer antigen 125; PDS, primary debulking surgery; NAC, neoadjuvant chemotherapy; IDS, interval debulking surgery.